Medical Information

The medication of rivastigmine in special populations needs to be adjusted according to physiological status and organ function, involving key groups such as pregnancy, lactation, children, and liver and kidney dysfunction. The following classification explains the principles of medication and monitoring points to ensure the safety and effectiveness of treatment.

Pregnant women

Revimenib has clear embryotoxicity and should be avoided during pregnancy. Those who require medication must undergo a risk assessment and be informed of the risk of fetal abnormalities. Animal studies have shown that it can cause embryonic death and structural abnormalities, while human data is limited but the risk cannot be ruled out.

2 lactating women

There is currently no data on the distribution of drugs in breast milk. It is recommended to stop breastfeeding during the treatment period and within one week after the last administration. If continued breastfeeding is necessary, the balance between infant exposure risk and the benefits of breastfeeding should be evaluated.

3 individuals with reproductive potential

3.1 Female patients

Before treatment, it is necessary to confirm the pregnancy status, and efficient contraceptive measures should be used during the treatment period and within 4 months after the last dose. Hormonal contraceptives may require the use of barrier therapy as the medication may affect contraceptive effectiveness.

3.2 Male patients

During the treatment period and within 4 months after the last dose, ensure that the partner takes contraceptive measures. Animal data shows a reversible effect on sperm parameters, but the impact on human fertility is not yet clear.

4 pediatric patients

Suitable for children aged ≥ 1 year, the dose should be calculated based on the body surface area (160mg/m ² twice daily for those<40kg). Abnormal bone development needs to be monitored as animal experiments have revealed a risk of premature closure of growth plates.

5 elderly patients

Patients aged 65 and above have a slightly higher incidence of QTc prolongation and peripheral edema, and require enhanced electrocardiogram monitoring. Dose adjustment should be based on renal function status, but age itself does not constitute a basis for dose adjustment.

6 liver dysfunction

Mild to moderate liver dysfunction (TBIL ≤ 3 × ULN) does not require dose adjustment. Patients with severe liver injury lack data, and it is recommended to use caution and closely monitor for signs of liver function deterioration.

7 renal insufficiency

Mild to moderate renal insufficiency (CLcr30-89mL/min) does not require dose adjustment. Data on patients with severe and end-stage renal disease is missing. It is recommended to start with low doses and monitor toxicity reactions.